ClinicalTrials.Veeva

Menu
A

AOU Maggiore Della Carita | Oncology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Zanubrutinib
Lenalidomide
INCB050465
Odronextamab
Ifosfamide
Anastrozole
Sacituzumab
Etoposide
Giredestrant
Gemcitabine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 12 total trials

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the...

Enrolling
B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Odronextamab

The study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treate...

Enrolling
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Dexamethasone
Drug: Ifosfamide

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients who have one of two t...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safe...

Enrolling
Breast Cancer
Drug: Triptorelin
Drug: Anastrozole

The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a...

Enrolling
B-cell Malignancies
Drug: Zanubrutinib
Drug: Tislelizumab

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreat...

Active, not recruiting
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Drug: zanubrutinib
Drug: bendamustine

The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, an...

Enrolling
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Trial sponsors

BeiGene logo
Regeneron Pharmaceuticals logo
Incyte logo
Gilead Sciences logo
U
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems